Salud financiera de hoja de balance de Fulcrum Therapeutics
Salud financiera controles de criterios 6/6
Fulcrum Therapeutics tiene un patrimonio de los accionistas total de $235.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $257.7M y $22.5M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$236.22m |
| Patrimonio | US$235.19m |
| Total pasivo | US$22.50m |
| Activos totales | US$257.69m |
Actualizaciones recientes sobre salud financiera
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Recent updates
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Industry Analysts Just Upgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Revenue Forecasts By 83%
May 12We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely
May 07Fulcrum Therapeutics beats on revenue
May 06Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($242.2M) de FULC superan a sus pasivos a corto plazo ($13.7M).
Pasivo a largo plazo: Los activos a corto plazo de FULC ($242.2M) superan a sus pasivos a largo plazo ($8.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: FULC está libre de deudas.
Reducción de la deuda: FULC no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: FULC tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: FULC dispone de suficiente cash runway para 2.5 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.8% cada año.